TEL AVIV, Israel, March 16, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host a Key Opinion Leader (KOL) webinar on its CGuard Stent Platform and it’s MicroNet™ portfolio on Tuesday, March 22, 2022 at 2 p.m. Eastern Time.
The webinar will feature presentations from KOL’s Chris Metzger, MD, PhD, from Ballard Health, Adnan Siddiqui, MD, PhD, FACS, FAHA, FAANS, from State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences, and Sean Lyden, MD, from Cleveland Clinic, who will discuss the current unmet medical need in the carotid/neurovascular market, and how InspireMD’s products have the potential to offer a differentiated solution.
The InspireMD management team will provide a brief corporate overview and plans to utilize their proprietary MicroNet technology to make CGuard EPS and additional pipeline products the industry standard for sustained embolic protection, neurovascular protection, and stroke prevention.
A live question and answer session will follow. To register for the webinar, please click here.
Chris Metzger, MD, is Ballad Health’s System Chair of Clinical Research. The role of System Chair of Clinical Research is to oversee the advancement of clinical research activities within Ballad Health hospitals and clinics, including clinical trials. Dr. Metzger is a practicing interventional cardiologist who serves as director of Holston Valley Medical Center’s diagnostic catheterization and interventional labs. He has helped Holston Valley earn national and international acclaim in cardiology, and his work has led to significant growth in cardiac clinical trials and research.
Under Dr. Metzger’s leadership, the cardiology program at Holston Valley has performed as the No. 1 or No. 2 enroller in the United States and globally in at least 29 top research trials, including being the current leading enroller in four major trials. Advancements made through this work not only improved cardiac care for patients nationwide but have also given local patients first access to leading-edge treatments and therapies. He has also forged a strong professional relationship with Harvard Medical School. Seven times, he has hosted endovascular fellows to train at Holston Valley before completing their education.
Sean Lyden, MD is the Chairman of the Department of Vascular Surgery at Cleveland Clinic’s Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute.
Dr. Lyden earned his medical degree from the University of Cincinnati College of Medicine following an undergraduate degree from the University of Notre Dame. He served a residency in general surgery at the University of Tennessee Health Sciences Center in Memphis where he was inducted into the Alpha Omega Alpha Medical Honor Society. His training included a year long trauma research. He subsequently served a fellowship in vascular surgery at the University of Rochester-Strong Memorial Hospital, Rochester, NY.
Dr. Lyden performs more than 200 procedures each year. His specialty interests include failed endovascular aneurysm repair, drug coated balloon use in arterial disease, popliteal artery entrapment syndrome. Currently, he is involved in clinical trials studying various topics including thoracic and abdominal stent grafting; lower extremity interventional therapies with drug coated balloons, drug-eluting stents and percutaneous femoral popliteal bypass; carotid stenting; and deep venous thrombosis treatments.
He serves on the editorial boards of Endovascular Today and Annals of Vascular Surgery and serves as reviewer for several journals, including the Journal of Vascular Surgery, Annals of Vascular Surgery and the Journal of the American College of Surgeons. He has authored and co-authored more than 85 articles in leading publications, including the Journal of Vascular Surgery, New England Journal of Medicine and Circulation. He also has also authored chapters in several vascular textbooks.
Adnan H. Siddiqui, MD, PhD, FACS, FAHA, FAANS, is Professor and Vice Chairman in the Department of Neurosurgery (UBNS) at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences. He joined UBNS in December 2006. Dr. Siddiqui completed fellowship training in Interventional Neuroradiology, Cerebrovascular Surgery and Neurocritical Care from Thomas Jefferson University in Philadelphia. He completed his Neurosurgical residency at Upstate Medical University and received his PhD in Neuroscience from the University of Rochester and medical degree from Aga Khan University in Pakistan. He is a Fellow of the American Association of Neurological Surgeons, American College of Surgeons and American Heart Association. He is profoundly indebted to his mentors Nick Hopkins, Robert Rosenwasser, Charles Hodge and Shirley Joseph in shaping his career as a dual-trained cerebrovascular surgeon, clinician scientist and entrepreneur.
Dr. Siddiqui has over 500 peer reviewed publications, more than 50 chapters, almost 70,000 citations and an H index of 72. He is particularly proud of representing Buffalo and the U.S. at most major cerebrovascular conferences around the world with over 200 international presentations to date. He has designed, conducted and lead multiple major national and international clinical trials and currently serves as National and International Principal Investigator (PI) for multiple major funded multi-site trials. These efforts have significantly contributed to the success of the department, which was ranked 7th in academic impact in North America by the Journal of Neurosurgery.
He serves as Chief Executive and Chief Medical Officer for the Jacobs Institute, a medical innovation center focused on accelerating device development in vascular medicine based in Buffalo, NY.
He leads the Canon Stroke & Vascular Research Center (CSVRC) at University at Buffalo. In addition, he serves as the Director of the Neurosurgical Stroke Service at the Gates Vascular Institute in Buffalo, one of the busiest Comprehensive Stroke Services in New York State and the United States.
Dr. Siddiqui has continuously served on multiple scientific and educational committees of American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS) and Society of NeuroInterventional Surgery (SNIS). He is the Chairman of the Joint Section of Cerebrovascular Surgery of the AANS and CNS and Secretary for the SNIS. It has been a major focus for him to achieve consensus between the various organizations involved in fellowship training and credentialing for Neuroendovascular Surgery.
He serves as a Neurosurgeon Director on the Executive Committee of the SNIS Patient Safety Organization which runs the NVQI-QOD Quality Outcomes Registry.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR, and certain warrants are quoted on the Nasdaq under the symbol NSPRZ.
For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. For example, the company is using forward looking statements when announcing that it will discuss its potential products’ impact and the Company’s plans to utilize their proprietary MicroNet technology to make CGuard EPS and additional pipeline products the industry standard for sustained embolic protection, neurovascular protection, and stroke prevention. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
